GLSI (Greenwich LifeSciences) Pre-Tax Income: $-21.68 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLSI Greenwich LifeSciences Inc GLSI
32 GF Score
Price $15.70
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Pre-Tax Income?

Greenwich LifeSciences GLSI -16.20% 32 Pre-Tax Income is $-21.68 Mil as of Jun. 2026. GuruFocus rates GLSI with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Pretax income is the income that a company earns before paying income taxes. Greenwich LifeSciences's pretax income for the three months ended in Jun. 2026 was $-3.95 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-21.68 Mil. Greenwich LifeSciences's pretax margin was %.


Greenwich LifeSciences  (NAS:GLSI) Pre-Tax Income Explanation

Greenwich LifeSciences's Pretax Margin for the quarter that ended in Jun. 2026 is calculated as

Pretax Margin=Pretax Income/Revenue
=-3.949/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenwich LifeSciences Pre-Tax Income Related Terms


Greenwich LifeSciences Pre-Tax Income Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences Pre-Tax Income Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pre-Tax Income
Get a 7-Day Free Trial -4.57 -7.83 -8.89 -17.41 -19.36

Greenwich LifeSciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 -4.15 -7.92 -5.66 -3.95

GLSI vs PLX, DTIL, NERV: Pre-Tax Income Comparison

For the Biotechnology subindustry, Greenwich LifeSciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences Pre-Tax Income vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Pre-Tax Income falls into.


GLSI
32GF Score
Greenwich LifeSciences Inc GLSI
Pre-Tax Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Greenwich LifeSciences's Pretax Income for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-19.448+0+0+0.09+0
=-19.36

Greenwich LifeSciences's Pretax Income for the quarter that ended in Jun. 2026 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-4.022+0+0+0.073+4.4408920985006E-16
=-3.95

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pre-Tax Income →
What does a Pre-Tax Income of $-21.68 Mil mean?
Greenwich LifeSciences (GLSI) has a Pre-Tax Income of $-21.68 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Greenwich LifeSciences and its competitors.
Is Greenwich LifeSciences' Pre-Tax Income too high?
Greenwich LifeSciences' current Pre-Tax Income is $-21.68 Mil. Overall, Greenwich LifeSciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Pre-Tax Income compare to PLX and DTIL?
Greenwich LifeSciences' Pre-Tax Income of $-21.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current Pre-Tax Income is $-21.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Pre-Tax Income of $-21.68 Mil. The current Pre-Tax Income is $-21.68 Mil. Greenwich LifeSciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Pre-Tax Income is $-21.68 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
32GF Score

Get the complete analysis for GLSI

Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.70
Price